Biological oncology products are integral to cancer treatment, but their high costs pose
challenges to patients, families, providers, and insurers. The introduction of biosimilar …

Biologics are vital to the management of patients with rheumatic and musculoskeletal
diseases such as rheumatoid arthritis and other inflammatory and autoimmune conditions …

The introduction of biological drugs for the treatment of patients with psoriasis has
revolutionized treatment paradigms and enabled numerous patients to achieve disease …

Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the
treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept …

Biologics play an integral role in the treatment of cancer not only for their therapeutic effects
and ability to improve outcomes, but also as supportive care agents. Biologics are more …

A biosimilar is a biopharmaceutical product intended to be comparable to a previously
licensed biopharmaceutical agent. The goal of such products is to increase the accessibility …

Background Despite regulatory efforts to formalize guidance policies on biosimilars, there
remains a need to educate healthcare stakeholders on the acknowledged definition of …

Biological medicines have become a major market for the pharmaceutical industry, the
biologicals market was valued at US $254.9 billion in 2017 and is expected to reach US …

Introduction Biosimilars are gaining popularity in Latin America (LA). The biosimilars market
is expected to grow rapidly over the next decade as a cost-effective alternative to expensive …

The treatment of many diseases, particularly cancer, has been profoundly impacted by the
introduction of biologic therapies (biologics), which are incorporated into the treatment …